Cullinan Therapeutics Inc. is drawing attention in the options market, particularly with its December put option at a $9 strike price. Selling this put offers a potential 25.1% annualized return, but it comes with significant caveats. The put seller only benefits if the stock drops 32.1% to trigger the contract, resulting in a cost basis of $7.35 per share, after accounting for the premium collected. This scenario highlights the limited upside compared to directly owning shares.
The stock’s historical volatility stands at 73%, indicating substantial price fluctuations, which could impact the attractiveness of this options strategy. With the stock currently trading at $13.20, the decision to sell the put should be weighed against both historical performance and fundamental analysis. Additionally, the broader options market is seeing increased put activity, with a put:call ratio of 0.72, suggesting a higher-than-expected demand for downside protection among traders.
For market professionals, the key takeaway is the need to balance potential returns against risks when engaging in options strategies, particularly in a volatile environment like that of Cullinan Therapeutics.
Source: nasdaq.com